By the Top Tier Newswire AI Desk · August 20, 2026 at 12:36 PM ET · reviewed against 158 wire stories
MODERNA INC (MRNA) is down -24.75% in the latest session. Our newswire has captured 158 stories on MRNA across 28 sources in the last 36 hours, with AI sentiment reading bullish (avg 66/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Moderna Inc (NASDAQ:MRNA) shares fell 24.75% to $131.23 on Thursday, reversing much of Wednesday’s historic 177% surge on cancer vaccine trial results. The sharp decline followed a volatile intraday session marked by a large gap down and heavy volume. The stock’s reversal came as market participants digested the magnitude of the prior day’s gains and the company’s underlying fundamentals.
What Happened
The stock opened at $158.44, a -9.1% gap from the prior close of $174.38. By midday, it had fallen to a session low of $130.35. The drop came as traders unwound positions after Wednesday’s extraordinary rally, which was driven by positive Phase 3 data for Moderna’s personalized cancer vaccine. The reversal was also influenced by a broader market reaction to external factors, including geopolitical tensions and broader biotech sector dynamics. UBS raised its price target to $150 but maintained a neutral stance, while analysts highlighted the challenge of aligning the stock’s valuation with its current lack of profitability.
What The Data Shows
Moderna’s fundamentals remain weak: it is unprofitable with a trailing twelve-month (TTM) net loss of $8.01 per share, revenue down 27.6% TTM, and a net margin of -141.4%. The stock has traded between $22.28 and $176.66 over the past 52 weeks. Intraday volume reached 45.6 million shares, or 6.4 times the 3-month average. Unusual options activity totaled $817.7 million in premium, with calls outpacing puts. Insiders have sold $35.7 million in the last 90 days, and the stock printed 16 fresh 52-week lows on August 20.
What To Watch
Moderna has no scheduled earnings report in the immediate future. Investors should monitor the breadth of analyst coverage and the sustainability of the recent biotech sector rally, as well as any follow-up data releases or regulatory developments related to the cancer vaccine program.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
MRNA · Aug 20 session (5-min) · -25.45% vs prior close · updated 8:58 PM ETAI sentiment, last 36h · averaged over 158 stories · 66/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
23d agoYahoo FinanceBEARISH 34Earnings
Moderna Plunges 20% One Day After Cancer Vaccine Breakthrough Sent Shares Up 177%
Moderna (NASDAQ:MRNA) shares have crashed 20% as of 12:00 PM ET on Thursday after delivering one of the biotech sector’s most extraordinary single-day moves of 2026. CNBC co-anchor Andrew Ross Sorkin told viewers that Moderna’s Phase 3 results for its experimental cancer vaccine sent the stock soaring 177% on Wednesday, while partner Merck (NYSE:MRK) rallied ... Moderna Plunges 20% One Day After Cancer Vaccine Breakthrough Sent Shares Up 177%
The biopharmaceutical sector has struggled with a prolonged downturn in recent years but has been on an upswing of late.
23d agoYahoo TopBEARISH 34Earnings
Moderna Sinks 18% After 177% Cancer Vaccine Rally, BioNTech Falls 4%, Merck Slips
Shares of Moderna (NASDAQ:MRNA) stock are down 18% to $142.70 in Thursday midday trading, unwinding a meaningful piece of Wednesday’s historic 177% rally. The reversal follows a Phase 3 win for Moderna’s personalized cancer vaccine, a result that repriced Moderna stock so violently in one session that a retrace looked close to inevitable. BioNTech (NASDAQ:BNTX) ... Moderna Sinks 18% After 177% Cancer Vaccine Rally, BioNTech Falls 4%, Merck Slips
23d agoInvesting.com MarketsNEUTRAL 53General
Moderna stock analysis: mRNA cancer win meets zero-profit fundamentals
Moderna stock analysis: mRNA cancer win meets zero-profit fundamentals
23d agoTipRanksBEARISH 32Earnings
Why Moderna Stock Is Plunging Today — and What Wall Street Sees Ahead
Moderna (NASDAQ:MRNA) stock is giving back part of Wednesday’s huge gain, falling about 18% on Thursday as Wall Street’s response to the latest cancer-vaccine resul...
23d agoInvesting.com MarketsNEUTRAL 50General
SpaceX, Moderna among market cap stock movers on Thursday
SpaceX, Moderna among market cap stock movers on Thursday
23d agoSeeking AlphaBULLISH 56Analyst
Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
Merck (MRK) stock slips as RBC Capital Markets cuts on valuation while Morgan Stanley upgrades on trial data for Moderna (MRNA)-partnered cancer shot. Read more here.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →